In the past, we described that targeting SLAMF6 with its soluble ectodomain yielded CD8+ T cells that do not need IL-2 supplementation, either in vitro or in vivo, to eradicate established melanoma (Eisenberg et al., 2018). Here, SLAMF6 is linked to melanoma.